"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Descriptor ID |
D006689
|
| MeSH Number(s) |
C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
|
| Concept/Terms |
Hodgkin Disease- Hodgkin Disease
- Disease, Hodgkin
- Granuloma, Hodgkin's
- Hodgkin's Granuloma
- Granuloma, Hodgkins
- Hodgkins Granuloma
- Lymphogranuloma, Malignant
- Lymphogranulomas, Malignant
- Malignant Lymphogranuloma
- Malignant Lymphogranulomas
- Hodgkin Lymphoma
- Lymphoma, Hodgkin
- Hodgkin's Disease
- Disease, Hodgkin's
- Hodgkin's Lymphoma
- Hodgkins Lymphoma
- Lymphoma, Hodgkin's
- Hodgkins Disease
- Disease, Hodgkins
- Granuloma, Hodgkin
- Hodgkin Granuloma
- Granuloma, Malignant
- Malignant Granuloma
- Malignant Granulomas
|
Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".
Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".
This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 3 | 1 | 4 |
| 1998 | 7 | 1 | 8 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 2 | 4 |
| 2002 | 4 | 2 | 6 |
| 2003 | 5 | 0 | 5 |
| 2004 | 5 | 0 | 5 |
| 2005 | 1 | 1 | 2 |
| 2006 | 3 | 2 | 5 |
| 2007 | 6 | 0 | 6 |
| 2008 | 3 | 1 | 4 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 4 | 1 | 5 |
| 2013 | 5 | 0 | 5 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 5 | 0 | 5 |
| 2017 | 4 | 2 | 6 |
| 2018 | 7 | 0 | 7 |
| 2019 | 5 | 0 | 5 |
| 2020 | 6 | 0 | 6 |
| 2021 | 3 | 1 | 4 |
| 2022 | 4 | 0 | 4 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16; 145(3):290-299.
-
When to use stem cell transplantation for classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):517-523.
-
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 10 17; 391(15):1379-1389.
-
At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Sep 01; 120(1):1-9.
-
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024; 13(1):2388304.
-
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Arch Pathol Lab Med. 2024 Aug 01; 148(8):914-920.
-
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 07 09; 8(13):3360-3371.
-
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. Cancer Res Commun. 2024 07 01; 4(7):1726-1737.
-
Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatr Blood Cancer. 2024 Aug; 71(8):e31091.
-
Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e432420.